Randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring

Pharmacotherapy

Volumn 26, Issue 7 I, 2006, Pages 889-895

  Maciejewski, Stephanie ^a   Mohiuddin, Syed M ^a   Packard, Kathleen A ^a   Mooss, Aryan N ^a   Reyes, Antonio P ^a   Aryana, Arash ^a   Hilleman, Daniel E ^a  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

ABPM; African Americans; Ambulatory blood pressure monitoring; Amlodipine; Hypertension; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; MALE; PARESTHESIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE;

ADULT; AFRICAN AMERICANS; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; TETRAZOLES; VALINE;

EID: 33745698991     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.7.889     Document Type: Article

References (18)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the administration of hydrochlorothiazide. Br J Clin Pharmacol 1982;14:97-101.
2. Materson BJ, Reda DJ, Cushman WC, et al. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;3281:914-21.
3. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients: the trandolapril multicenter study group. Hypertension 1995;26:124-30.
4. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. The renin-angiotensin system and blood pressure: differences between blacks and whites. Am J Hypertens 1999;12:555-62.
5. Luft HC, Grim CE, Weinberger MH. Electrolyte and volume homeostasis in blacks. In: Hall WD, Saunders E, Shulman NB, eds. Hypertension in backs: epidemiology, pathophysiology and treatment. Chicago, IL: Year Book Medical Publishers, 1985:115-31.
6. Laragh JH, Sealey JE. Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity and find the best-fit drug regimen. In: Laragh JH, Brenner BM, eds. Hypertension pathophysiology, diagnosis and management, 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins, 1995:1813-36.
7. Association of Black Cardiologists (ABC) Candesartan Study Group. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC trial. Heart Dis 2000;2:392-9.
8. Conlin PR, Erlinger TP, Bohannon A, et al. The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am J Hypertens 2003;16:337-42.
9. Flack JM, Saunders E, Gradman A, et al, for the Study Group for Losartan in African Americans with Hypertension. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193-208.
10. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.
11. Weir MR, Smith DHG, Neutel JM, Bedigan MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 2001;14:665-71.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
13. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004;43:566-72.
14. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178-87.
15. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
16. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002;40:311-17.
17. Wright JT, Bakris G, Greene T, et al, for the African American Study of Kidney Disease and Hypertension Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
18. Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley J, Zelenkofske S, for the AADVANCE Investigators. A noninferiority comparison of valsartan/ hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 2005;46:508-13.